No Picture
Trading Ideas

Pfizer’s biosimilar of Amgen, J&J’s anemia treatments gets FDA nod

Pfizer Inc’s Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands. A year ago the U.S. Food and Drug Administration rejected Retacrit as a copy of Amgen’s Epogen and Johnson & Johnson’s Procrit, citing https://investors.pfizer.com/investor-news/press-release-details/2017/Pfizer-Provides-Update-on-Proposed-Epoetin-Alfa-Biosimilar/default.aspx issues with a potential manufacturing facility in Kansas. …read more […]

No Picture
Trading Ideas

As lava destroys Hawaii homes, owners ask: Am I covered?

Patricia Deter moved from Oregon to Hawaii to be closer to her two daughters, but the Kilauea volcano burned down her home only a month after she bought it. Now Deter and others who have recently lost homes to the lava-spewing mountain are on an urgent quest for answers about insurance, desperate to learn whether their coverage will offer any help after molten rock wiped out most of what they owned. The eruption has destroyed about two dozen homes in the Leilani Estates subdivision on the Big Island. …read more […]

No Picture
Trading Ideas

Tax Changes Force Cash-Hoarding Companies to Sell Bonds

Cash-rich companies that had been some of the biggest buyers of corporate bonds have started selling their holdings after tax law changes, according to Bank of America Corp. strategists. Companies like Apple Inc. reduced their corporate bond portfolios by more than 10 percent to $306.4 billion in the three months ended March 31, the lowest level in more than a year, after buying around $10 billion of the bonds on average every quarter. About half of that decline came from selling, and the other half from securities maturing, strategists led by Hans Mikkelsen wrote. …read more […]